Johnson & Johnson (NYSE:JNJ) on Wednesday mentioned that its esketamine nasal spray Spravato confirmed superior efficacy in comparison with quetiapine extended-release (XR) in adults with treatment-resistant main depressive dysfunction (TRD) in a section 3b trial.
Quetiapine, amongst others, is offered as Seroquel and was earlier marketed by AstraZeneca (NASDAQ:AZN) till the British pharma large offered the rights to the drug to Luye Pharma for sure worldwide markets, and to Cheplapharm for the U.S. and Canadian market.
Seroquel was primarily used to deal with schizophrenia and bipolar dysfunction has misplaced its compound patent safety globally.
The research, dubbed ESCAPE-TRD, included 676 adults with TRD who acquired both Spravato (n=336) or quetiapine XR (n=340), each together with a seamless selective serotonin reuptake inhibitor (SSRI) or serotonin and norepinephrine reuptake inhibitor (SNRI).
The trial met its foremost objective as extra individuals on Spravato (27.1%) achieved remission at week 8, in comparison with quetiapine XR (17.6%), J&J’s Janssen Pharmaceutical mentioned in a press launch.
The research additionally met its key secondary objective, exhibiting that considerably extra individuals on Spravato (21.7%), in comparison with quetiapine XR (14.1%) achieved remission at week 8, with no relapse as much as week 32, the corporate added.
Janssen famous that remission charges continued to extend in each teams after the first objective at week 8 with a considerably higher proportion of sufferers in remission at week 32 within the Spravato group (55%), versus quetiapine XR arm (37%).
“We’re happy to see that esketamine nasal spray has been demonstrated to be efficient and well-tolerated versus a powerful augmentation comparator therapy in enabling individuals to attain the objectives of attaining remission and remaining relapse free as much as 32 weeks – essential and significant milestones in treating TRD,” mentioned Tamara Werner-Kiechle, EMEA Therapeutic Space lead, Neuroscience and Pulmonary Hypertension, Janssen-Cilag, a part of Janssen.
The corporate added that the commonest (≥10%) treatment-emergent adversarial occasions (TEAEs) seen within the Spravato group have been dizziness (46.7%), nausea (29.3%), dissociation (28.1%), headache (24.6%) and vertigo (18.9%), amongst others. These outcomes have been in line with security knowledge collected in earlier research, in accordance with the corporate.
Janssen mentioned critical TEAEs have been seen in 5.1% of individuals within the quetiapine XR arm and 5.7% within the Spravato group.
In the meantime, 23.2% of the individuals within the Spravato group discontinued remedy, in comparison with 40.3% within the quetiapine XR arm, Janssen addded.
Spravato, to be used together with an oral antidepressant, was authorized within the U.S. in March 2019 to deal with adults with treatment-resistant melancholy.